BARCELONA, Spain — A new phase 3 trial of ocrelizumab in primary progressive multiple sclerosis (PPMS) showed meaningful benefit in older patients and those with advanced disease — a first for this ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib, delayed ...

Researchers from Kyushu University have identified a potential therapeutic target for the treatment of advanced multiple sclerosis (MS), a potentially disabling condition associated with the central ...

An experimental drug can delay disability progression in advanced multiple sclerosis patients Tolebrutinib delayed disability progression by 31% in people with secondary progressive multiple sclerosis ...

ECTRIMS 2025 Head-to-Head Trial Supports New Treatment for Kids With MS A multicenter phase 3 trial comparing ocrelizumab to fingolimod for children with MS achieved its noninferiority primary ...